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ABSTRACT 
Objective: To investigate the interaction of Lfcin B (Lactoferricin B) with GSTP1 (Glutathione S-Transferase P1) from human placental and breast 
cancer cell line MDA-MB-231.  
Methods: We examined the interaction of Lfcin B with human placental GSTP1 and breast adenocarcinoma MD-MB-231 cell line. Enzyme activity of 
GSTP1 was measured with and without pre-incubation with Lfcin B. Kinetic variables were determined by incubating the enzyme reaction mixture 
with fixed GSH (reduced glutathione) concentration and varying CDNB (1-chloro-2, 4-dinitrobenzene) concentrations or fixed CDNB concentration 
and varying GSH concentrations.  
Results: Lfcin B is a competitive inhibitor with respect to GSH binding site (G site) and noncompetitive inhibitor with respect to hydrophobic 
substrate unit (H site) of human placental GSTP1 enzyme. Lfcin B was also incubated with GSTP1 from breast adenocarcinoma MDA-MB-231 cell 
line. The activity of GSTP1 was much higher (0.2665 μ mol/ml/min) in Lfcin B untreated MDA-MB-231 cell line, whereas MDA-MB-231 with Lfcin B 
treatment showed a very low activity (0.0254 μ mol/ml/min). 
Conclusion: Our Findings suggest that Lfcin B can inhibit the GSTP1 activity in human placental and MDA-MB-231 breast cancer cell lines, which 
may induce synergistic effects when used in combination with antineoplastic drugs that are substrates of GSTP1 enzyme. This combination will 
exert a double attack on cancers over expressing GSTP1, first sensitizing them to anticancer drugs by preventing their metabolism. 
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INTRODUCTION 
Glutathione S-transferases (GSTs) belong to a family of phase II drug 
metabolizing enzymes that catalyzes the conjugation of tripeptide 
glutathione (GSH) with electrophilic compounds resulting in the 
formation of corresponding conjugates [1]. The active site of GSTs 
exists as dimer with two functional regions; a hydrophobic site (H-
site) where, electrophilic substrates bind and a hydrophilic GSH 
binding expression site (G-site) [2]. GSTs, especially Glutathione S-
transferase P1 (GSTP1) isoform have been reported to play an 
important role in the development of tumoral drug resistance [3]. 
GSTP1 isoform has been reported to in a variety of cancer including, 
breast, lungs, ovary, pancreas, melanoma, brain, kidney, colon and 
leukemia [4-12] Beside exogenous and endogenous toxic 
compounds, several chemotherapeutic agents including, cisplatin, 
chloroambucil, doxorubicin, melphalan, cyclophosphamide, 
ifosphamide and thiotepa have been demonstrated to be the 
substrates of GSTP1 [13]. During the last decade, non-detoxifying 
functions of GSTP1 have emerged, providing the enzyme with 
significant biological importance. GSTP1 has been shown to interact 
with different proteins and modulate signaling pathways controlling 
proliferation, apoptosis and differentiation. For example, GSTP1 
binds to and inhibit c-Jun-N-terminal kinase (JNK) thus, playing a 
significant role in apoptosis and cell signaling [14]. These regulatory 
functions of GSTP1 suggest why cancers over expressing GSTP1 
show drug resistance towards drugs that are not its substrates. 
Recently GSTP1 has been demonstrated to undergo phosphorylation 
by protein kinase C (PKC) and epidermal growth factor receptor 
(EGFR), leading to increase in catalytic efficiency of GSTP1 which 
further contributes to drug resistance. [15-17]. Though 
consequences of non-enzymatic functions of GSTP1 are still being 
elucidated, there is enough evidence to suggest that pharmacological 
inhibition of GSTP1 may be useful for the treatment of cancer. GSTP1 
inhibitors presently under pre-clinical and clinical trials include 
ethacrynic acid, TLK-286, TLK 199, 6-(7-nitro-1,2,3-benzoxadiazol-
4-ylthio) hexanol (NBDHEX), 4-aminobenzoic acid/nitric oxide 
(PABA/NO) and bromosulfophthalein [18]. TLK-286 and NBDHEX 
have also have been demonstrated to block the interaction of GSTP1 
with JNK leading to sensitization of cancer cells to alkylating agents 
[19, 20]. In spite of various inhibitors there is a need of new 
inhibitors since toxicity of the reported compounds limit their use in 
clinic.  
During the last decade, peptide has been established as an effective 
therapeutic option for the treatment of cancer [21]. Bovine 
lactoferricin (Lfcin B) is a cationic amphipathic peptide produced by 
acid pepsin hydrolysis of bovine lactoferrin (bLF) and reported to 
exhibit anticancer, antimicrobial and antifungal properties [22]. 
Burrow et al. showed interaction of selenium saturated bovine 
lactoferrin (Se-bLF) with [(GSH)/GPx (Glutathione 
Peroxidase/Glutathione Reductase) GR/GST (Glutathione S-
Transferase) [23]. However, there is no report examing the 
interaction between Lfcin B and GSTP1. In this study, we reported 
that Lfcin B is a competitive inhibitor of human placental GSTP1 also 
we had shown Lfcin B decreases the GSTP1 activity in MDA-MB-231 
breast cancer cell lines and could be developed as an alternate to 
existing inhibitors. Finding suggest that Lfcin B may exert a double-
barrel attack on cancer cells; first by acting as an anticancer agent 
itself and secondly by inhibiting GSTP1, thereby, sensitizing cells to 
chemotherapeutic drugs that are either substrates of GSTP1 or 
induce apoptosis by activating JNK. 
MATERIALS AND METHODS 
Materials 
Reduced glutathione (GSH), human placental glutathione S-
transferase P1 (hp-GSTP1) and 1-chlro-2, 4-dinitro benzene (CDNB) 
were purchased from Sigma Aldrich (New Delhi, India). Lfcin B (with 
sequence RRWEWRMKKLG), was custom designed at BioConcept 
Lab Pvt. Ltd. (IMT Manesar, Gurgaon, India.) MDA-MB-231 cell, 
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culture media, fetal calf serum and Hank’s basal salt solution was 
brought from Institute of Nuclear Medicine and Allied Sciences (New 
Delhi, India). All other reagents were purchased from Sigma-Aldrich 
unless otherwise stated.  
Methods 
GSTP1 enzymatic assay 
GSTP1 activity assay was determined following the method of Habig 
et al. 1974 by measuring GSH conjugation with CDNB [24]. Briefly, 
the reaction mixture contained 0.1 M potassium phosphate buffer 
(pH 6.8), 1 unit/ml hp-GSTP1 or 25µg protein from cell lysates, GSH 
and CDNB. The rate of product formation was monitored by 
measuring the change in absorbance at 340 nm using a Shimadzu UV 
1800 Spectrophotometer. The enzyme activity was calculated after 
correction for non enzymatic reaction. The molar absorption 
coefficient for CDNB was Δє340 = 9.6 mM-1 cm-1.  
Determination of steady-state kinetic parameters 
Steady-state kinetics of GSTP1 was carried out at a constant GSH 
concentration of 2.5 mM, by varying CDNB concentration (0.5-4.0 
mM) keeping CDNB concentration at 1.0 mM and varying GSH 
concentration (0.125-2.5 mM). All assays were performed in 0.1 mM 
potassium phosphate buffer (pH 6.8) containing 1 unit/ml hp-GSTP1 
in the presence or absence of Lfcin B. Experimental data were 
plotted with Line weaver-Burk plot and kinetic parameters 
determined using the Michaleis-Menten equation.  
Kinetics of enzymatic inhibition 
A reaction mixture containing 0.1 M potassium phosphate buffer (pH 
6.8), 1.0 unit/ml hp-GSTP1 and 1 µM Lfcin B was prepared and 
incubated in a water bath set at 37 ºC for enzyme activity. Aliquots 
(350 µl) were withdrawn for enzyme activity assay and the 
remaining solution transferred back to the water bath. Aliquots 
were withdrawn at 1,5,10,15,30,45 and 60 min mixed with 125 µl of 
10 mM GSH and 50 µl of 10 mM CDNB and GSTP1 activity 
determined spectrophotometrical as described above. 
Inhibition of GSTP1 activity in cells 
MDA-MB231 cells were cultured in serum free DMEM/F12 
(Dulbecco’s Modified Eagle’s medium) media in 100-cm2 dishes. 
They were treated with 100 μM Lfcin B for 6 h. After treatment cells 
were harvested using a cell scraper, lysed in 1 ml of 50 mM Tris-Hcl 
buffer (pH 7.4) containing 1 mM DTT (Dithiothreitol), 1 mM PMSF 
(phenylmethylsulfonyl fluoride), 100 μM Na3VO4 and 2 μg/ml 
aprotinin and centrifuged at 20,000 x g for 20 min at 4 ºC. 
Supernatants were collected and protein concentration determined 
by Lowry’s method. Another set of cultures dishes were similarly set 
but without Lfcin B treatment, which served as a control. GSTP1 
activity in the cell lysates was measured using CDNB and GSH as 
substrates, as described above and expressed as n mol/min/mg 
protein. 
Total protein determination  
Total protein contents for each samples in the particle-free 
supernatants were determined spectrophotometrically according to 
the Folin-Ciocalteu reagent (FCR) method described by Lowry et al. 
(1951) using bovine serum albumin (BSA) as standard. Absorbance 
at 660 nm against the blank measured. A standard graph drawn, the 
amount of protein in the sample calculated and results expressed as 
µg protein/g sample.  
Statistical analysis 
Enzyme activity data curves were fitted using a non-linear 
regression program (GraphPad Prism, San Deigo, CA, USA) to 
calculate the maximum velocity of substrate formation (Vmax) and 
the Michaelis constant (KM) for substrate affinity determined using 
the following equation:  
Y= (Vmax) (S)/(Km+S) 
Where; Y represents enzyme activity (μmol/min/mg) and S 
represents substrate concentration (mM). 
RESULTS 
Kinetic profiling of human placental GSTP1 in response to Lfcin B  
The Km values for GSH (Varied) and CDNB (varied) were found to be 
0.75±1.0 and 0.63±0.59 mM, respectively. The Vm values were 
varying according to the fixed substrate. When CDNB was fixed 
substrate (1 mM), Vm value obtained was 0.75±0.44 U/mg protein 
but when GSH is the fixed substrate (1 mM), a lower value for Vm 
was obtained: 0.38±0.14 U/mg protein (table 1). 
 
Table 1: The kinetic parameters of substrates and Lfcin B inhibition of GSTP1 
Substrates Vm (U/mg protein) Km, mM 
Varying GSH 0.75±0.44 0.75±1. 0 
Varying CDNB 0.38±0.14 0.63±0.59 
 
The total protein content of MDA-MB-231 cell line of treated and 
untreated with Lfcin B determined spectrophotometrically by 
Lowry’s method were 9.3 µg and 7.3 µg respectively. The GSTP1 
enzyme activity in MDA-MB231 treated with Lfcin B and without 
any treatment showed a difference. The activity of GSTP1 was much 
higher (0.2665 µ mol/ml/min) in control (Lfcin B untreated) cell 
line, whereas MDA-MB231 with Lfcin B treatment showed a very 
low activity (0.0254 µ mol/ml/min). (table 2). 
 
Table 2: Total protein and GSTP1 activity in MDA-MB231 cells in untreated and Lfcin B treated groups 
Cancer Cell line groups MDA-MB231 (Untreated) MDA-MB231 (Lfcin B treated) 
Total Protein 7.3 µg 9.3µg 
GSTP1 Activity 0.2665 µ mol/ml/min 0.0254 µ mol/ml/min 
 
DISCUSSION  
In recent years, studies of GSTs have revealed new roles for some of 
the members of this family. It has been demonstrated that GSTs of 
classes’ alpha, mu, and pi are involved in cell proliferation, 
differentiation and control of cell death via interactions with special 
signaling proteins [22, 23, 30]. In particular, GSTP1 is over 
expressed in some cancer cells and it has been reported to be 
responsible for tumoral drug resistance [25] Therefore, the use of 
inhibitors to suppress the GSTP1 activity in cancer cells is a 
promising method to overcome such drug resistance. New GSTP1 
inhibitors with better efficacy are required. Recently peptides have 
been reported to exert anticancer effects [26]. Examples Lfcin B and 
Lactoferrin have various anticancer properties [27, 28]. Here we 
report Lfcin B is the competitive inhibitor (with respect to G site) 
and non-competitive inhibitor (with respect to H site) of GSTP1 
enzyme (fig. 1), (fig. 2) and (fig. 3). In Lactoferricin interaction with 
human placental GSTP1 the differences in Vm values could be 
explained by the controversial effects of the substrates on GSTP1; 
high GSH converts GSTP1 to a more active conformation but high 
CDNB to a less active conformation. In addition the treatment of 
Lfcin B with breast cancer MDAMB231 cells, we noted a difference 
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between the GSTP1 levels supporting our hypothesis that Lfcin B 
inhibits the GSTP1 activity as shown invitro human placental GSTP1 
and in cell line MDA-MB-231. Lfcin B is formed by acid pepsin 
hydrolysis of Lactoferrin naturally occurring in stomach. Lactoferrin 
have not been known for any major side effects. In very high doses 
diarrhea, skin rash, loss of appetite, fatigue, chills, and constipation 
have been reported [29]. We hypothesize that Lfcin B can modulate 
GSTP1 by three proposed pathways (1) by directly interacting with 
GSTP1 and inhibiting its active site, (2) by inhibiting GSTP1 binding 
with JNK and cJun, (3) by inhibiting GSTP1 complex formation with 
TNF receptor-associated factor 2 (TRAF2) and apoptosis signal-
regulating kinase (ASK) (fig. 4). Activation of GSTP1 has been shown 
to be involved in anticancer drug resistance [30]. JNK has been 
shown to be associated with stress response, apoptosis, 
inflammation, and cellular differentiation and proliferation [31]. 
Moreover ROS and other stress response lead to JNK activation and 
phosphorylation of cJun which is involved in development of chemo 
sensitization (fig. 4). It has been found that GSTP1 inhibits (TRAF2) 
activation of JNK and p38 Mitogen associated protein kinase (p38-
MAPK) [32]. Furthermore GSTP1 attenuates TRAF2-ASK induced 
apoptosis [32]. We think that Lfcin B might inhibit GSTP1 interaction 
with TRAF2 and ASK (fig. 4). Further studies are required to study 
the detailed mechanisms of this proposed hypothesis.  
 
 
Fig. 1: GSTP1 inhibiting by Lfcin B at 1.0 mM CDNB and varying 
GSH concentration (0.125-2.5 mM) 
 
 
Fig. 2: GSTP1 inhibiting by Lfcin B at 2.5 mM GSH and varying 
CDNB concentration (0.5-0.4 mM) 
 
 
Fig. 3: (a) GSTP1 molecule showing H and G: (b) Lfcin B peptide: 
(c) Lfcin B is a competitive inhibitor (with respect to G site) and 
non competitive inhibitor (with respect to H site) of GSTP1 
enzyme; (d) Inhibited GSTP1 prevented from binding with JNK 
 




Our findings suggest that Lfcin B can be used in combination with 
drugs known to be substrates of GSTP1 enzyme. This combination 
will exert a double attack on cancers overexpressing GSTP1, first 
sensitizing them to anticancer drugs by preventing there 
metabolism and secondary Lfcin B themselves will act as an 
anticancer peptide.  
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